Zydus vaccine for kids likely to be available by Oct, says Centre

NEW DELHI: Zydus Cadila’s anti coronavirus disease (Covid-19) vaccine, ZyCov-D, the first approved for use on people as young as 12 in the country, is likely to be available by the first week of October, Union health secretary Rajesh Bhushan said during a briefing by the health ministry on Thursday.

It still isn’t clear whether the vaccine will form part of the country’s ongoing drive to vaccinate all adults by the end of the year, or be reserved for the use of children.

Currently, only those over the age of 18 years are eligible for vaccines in India. Responding to reports that the children with co-morbidities that made them more vulnerable to serious illness and death from Covid will be prioritised, Bhushan said this was an issue on which “the standing committee on Covid of NTAGI makes a recommendation to the full NTAGI”.

With a 10-million per month capacity by October, the Zydus vaccine will add to overall supply of the jabs in India, albeit to a small extent. In an analysis published on Wednesday, HT pointed out that the country needs to deliver 10 million shots a day between now and the end of the year to meet its target of vaccinating all adults.

On August 20, India’s drugs regulator approved the Zydus Cadila vaccine for emergency use. ZyCoV-D, the world’s first plasmid DNA vaccine for Covid-19, is a three-dose vaccine which will be administered on Day zero, Day 28, and Day 56.

Bhushan, however, said it was too early to comment on whether the vaccine will be allowed for all children in one go or for those children who suffer from comorbidities.

Vaccinating children could help the re-opening of schools. Although research has shown that a high level of coverage among adults also reduces infections among children, India is nowhere close to that. Till Thursday, around 50% of the eligible adults in the country had received at least one dose of the Covid-19 vaccine.

Experts said that , however, say, if supplies are short then it makes sense to first vaccine children with comorbidities.

The vaccine was approved by the CDSCO after its experts assessed results from the company’s phase III clinical trials that showed the vaccine to have an efficacy of 66.6%.